We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
- Authors
Díez‐Campelo, María; Lorenzo, Jose I.; Itzykson, Raphael; Rojas, Silvia M.; Berthon, Céline; Luño, Elisa; Beyne‐Rauzy, Odile; Perez‐Oteyza, Jaime; Vey, Norbert; Bargay, Joan; Park, Sophie; Cedena, Teresa; Bordessoule, Dominique; Muñoz, Juan A.; Gyan, Emmanuel; Such, Esperanza; Visanica, Sorin; López‐Cadenas, Félix; de Botton, Stéphane; Hernández‐Rivas, Jesús M.
- Abstract
Summary: Treatment with azacitidine (AZA) has been suggested to be of benefit for higher‐risk myelodysplastic syndrome (HR‐MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR‐MDS patients with Abn 7 treated with AZA (<italic>n</italic> = 115) <italic>versus</italic> best supportive care (BSC;<italic> n</italic> = 120), assessed AZA treatment as a time‐varying variable in multivariable analysis. A Cox Regression model with time‐interaction terms of overall survival (OS) at different time points confirmed that, while chromosome 7 cytogenetic categories (complex karyotype [CK] <italic>versus</italic> non‐CK) and International Prognostic Scoring System risk (high <italic>versus</italic> intermediate‐2) retained poor prognosis over time, AZA treatment had a favourable impact on OS during the first 3 years of treatment compared to BSC (Hazard ratio [HR] 0·5 <italic>P</italic> < 0·001 at 1 year, 0·7 <italic>P</italic> = 0·019 at 2 years; 0·73 <italic>P</italic> = 0·029 at 3 years). This benefit was present in all chromosome 7 categories, but tended to be greater in patients with CK (risk reduction of 82%, 68% and 53% at 1, 3 and 6 months in CK patients; 79% at 1 month in non‐CK patients, <italic>P</italic> < 0·05 for all). AZA also significantly improved progression‐free survival (<italic>P</italic> < 0·01). This study confirms a time‐dependent benefit of AZA on outcome in patients with HR‐MDS and cytogenetic abnormalities involving chromosome 7, especially for those with CK.
- Subjects
AZACITIDINE; ANTIMETABOLITES; MYELODYSPLASTIC syndromes; CHROMOSOMES; CHROMOSOME abnormalities
- Publication
British Journal of Haematology, 2018, Vol 181, Issue 3, p350
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.15190